Nautilus Biotechnology Appoints Nick Nelson as Chief Business Officer
Former Illumina and Caris Life Sciences executive to accelerate the company’s market introduction of a next-generation, single-molecule proteomics analysis platform
San Carlos, CA and Seattle, WA, October 15, 2020 — Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for quantifying the human proteome, today announced the appointment of Nick Nelson as Chief Business Officer. Joining the company on the heels of Nautilus’ recent $76 million Series B funding, Mr. Nelson will drive the design and execution of the company’s business development activities, including partnerships, alliances, and community engagement.
“Anyone who’s worked with Nick knows that he is an exceptionally talented leader in the life sciences and biotechnology world,” said Sujal Patel, co-founder and CEO of Nautilus Biotechnology. “His rich business and market development expertise will complement our strong research and development organization to help ensure we maximize our platform’s opportunity to spark a transformation in biomedical research.”
“I’m deeply inspired by the potential I see in Nautilus and am energized by the opportunity to be a part of the team bringing this incredibly novel platform to market,” said Nick Nelson, Chief Business Officer, Nautilus Biotechnology. “I’ve been fortunate to be a part of the genomics revolution, creating entirely new markets and applications enabled by a significant advancement in sequencing technology. Nautilus has all of the elements necessary to lead the next 20-year wave of transformative research and applications in proteomics and advanced data analytics.”
“Nick brings a deep understanding of science and technology and, as importantly, an unwavering dedication to customer and partner success,” said Matt Posard, Founding Principal at Explore DNA, Nautilus Board member, and former SVP & Head of Sales at Illumina. “When I worked closely with Nick at Illumina, his passion and insistence on creating mutually beneficial relationships with customers and partners set him apart. I’m excited to see him bring that same focus and commitment to Nautilus.”
Mr. Nelson has extensive leadership experience with top-tier diagnostics, therapeutics and life science companies. Before joining Nautilus, he was Chief Business Officer at Caris Life Sciences where he led all business development and strategic partnerships, and also led the creation of industry leading products for biopharma and oncology therapeutic development. Prior to Caris, he was Vice President of Commercial and Corporate Development at Trovagene (now Cardiff Oncology), and before that spent 10 years at Illumina in positions spanning R&D, technical service, sales and business management. While at Illumina he held leadership positions in the New and Emerging Markets business where he established partnerships and collaborations enabling high growth genomics businesses. He received his Bachelor of Science degree in Cellular and Molecular Biology from San Diego State University.
About Nautilus Biotechnology, Inc.
Based in San Carlos, CA and Seattle, WA, Nautilus is a biotechnology company whose proteomics platform will deliver superior sensitivity far more quickly, more completely, and less expensively than is currently possible. By breaking through the limitations of existing technologies, and effectively democratizing proteomics, Nautilus will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and usher in a new era of personalized and predictive medicine.
Latest posts by Chris Frew (see all)
- Gyroscope Therapeutics, which has operations in King of Prussia, raises $148M - March 31, 2021
- TCR² Therapeutics Acquires Cell Therapy Manufacturing Facility & New VP of Technical Operations, Aaron Vernon - March 29, 2021
- Frederick Based Biotech Law Firm McBee Moore & Vanik IP, LLC Celebrates Five Years - February 18, 2021
- Heather Mudrick Joins Workforce Genetics to Lead Clinical Search Practice - February 12, 2021
- RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC - February 4, 2021